72-Year-Old Man with Heavily Pretreated RRMM
Sagar Lonial, MD, FACP, summarizes the case of a 72-year-old man with heavily pretreated, triple-class relapsed/refractory multiple myeloma (RRMM).
Related Articles
Lower Net Worth Linked to Higher Costs Post Bladder Cancer Treatment
For patients who underwent radical cystectomy for bladder cancer, those with lower net worth incurred higher costs posttreatment.
Diagnosis and Initial Management of cGVHD
This segment focuses on the key considerations for diagnosing cGvHD and the initial treatment approaches, including the use of corticosteroids and combination therapies. The discussion…
Evolving Treatment Paradigms with Amivantamab in Wild-Type NSCLC
Natasha Leighl, MD, MMSc, BSc, discussed the analysis of the CHRYSALIS study that was presented at the 2024 American Association for Cancer Research Annual Meeting.
KEYNOTE-859 Outcomes Influence NCCN Guidelines on Pembrolizumab in Upper GI Cancer
During a Case-Based Roundtable® event, David Zhen, MD, discussed how treatment of upper gastrointestinal cancer with pembrolizumab and chemotherapy is impacted by PD-L1 composite positive…
Lumisight, Lumicell DVS Gains FDA Approval to Detect Residual Breast Cancer
The FDA has approved Lumisight and the Lumicell Direct Visualization System for fluorescence imaging in adult patients with breast cancer.
Savona Discusses First-Line JAK Inhibition for Patients With Myelofibrosis at Risk of Anemia
During a Case-Based Roundtable® event, Michael Savona, MD, and participants discussed the case of a patient with myelofibrosis and moderate anemia receiving JAK inhibitor therapy.
Future Landscape of BPDCN Management
Dr. McCloskey discusses the limitations of current treatment options for BPDCN, as well as the emerging research and data that are most anticipated in the…
The Myeloma Trial Result I Did Not See Coming
A new drug called belantamab mafodotin significantly improved survival in relapsed multiple myeloma patients compared to a standard treatment.
Glofitamab Plus Chemo Improves Survival vs Rituximab in R/R DLBCL
The phase 3 STARGLO trial met its primary end point, improving overall survival in patients with relapsed/refractory diffuse large B-cell lymphoma with glofitamab and chemotherapy…
Monitoring and Mitigating Adverse Events
Exploring general principles and practices for monitoring and mitigating adverse events in patients with chronic GvHD treated with systemic agents, and determining when dose modification…